Table 2.

Coinhibition of PD-L1 and CD38 produces a favorable antitumor microenvironment

Infiltrating immune cells in LLC-JSP–bearing tumorsCombination therapy of anti–PD-L1 and anti-CD38Combination therapy of anti–PD-L1 and Rhein
Controlanti–PD-L1anti-CD38CombinationControlanti–PD-L1RheinCombination
% of CD8+ T cells5.05 ± 0.494.70 ± 0.329.15 ± 1.1920.80 ± 1.214.99 ± 0.554.78 ± 0.397.13 ± 0.7923.15 ± 0.82
% of CD44hi CD62Llo in CD8+ T cells50.90 ± 1.9046.10 ± 1.1864.48 ± 3.2975.10 ± 1.0450.68 ± 1.5941.55 ± 3.9755.84 ± 2.9870.36 ± 1.07
% of PD-1+TIM3+ in CD8+ T cells30.43 ± 2.1738.53 ± 2.9823.84 ± 1.6710.12 ± 0.8630.40 ± 1.4440.03 ± 4.3922.66 ± 1.9613.68 ± 1.47
% of CD4+ICOS+ T cells4.27 ± 0.466.26 ± 0.536.70 ± 0.659.20 ± 0.584.44 ± 0.476.72 ± 0.315.45 ± 0.508.78 ± 0.70
% of Tregs in CD4+ T cells10.63 ± 0.4513.90 ± 0.545.13 ± 0.302.83 ± 0.4710.75 ± 0.5615.25 ± 0.978.47 ± 0.724.77 ± 0.63
% of MDCSs in CD45+ cells24.38 ± 1.9830.53 ± 1.0111.50 ± 1.405.17 ± 1.1425.13 ± 2.1030.78 ± 1.1814.95 ± 1.948.66 ± 1.52